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Abstract
Background: There is limited information about the effect of diabetes on the prognosis of patients
with bacterial infections. We performed a retrospective cohort study to investigate possible
correlations between diabetes and prognosis in patients with Enterobacteriaceae bacteremia.
Methods: We reviewed the medical charts of 1112 patients who were treated at a community
teaching hospital for Enterobacteriaceae bacteremia from January 1997 through June 2007. Factors
associated with in-hospital mortality were analyzed by logistic regression analysis.
Results: Among the 1112 patients with Enterobacteriaceae bacteremia, 181 (16.3%) were diabetic
patients; 90 patients (8.1%) died while in the hospital. Compared to non-diabetic patients, diabetic
patients were older (75.4 ± 11.9 years vs. 70 ± 16.6 years, p < 0.001) and had more comorbidities.
However, mortality among diabetic and non-diabetic patients was not different [7.2% vs. 8.2%, RR
1.13; 95% CI (0.67–1.9); p = 0.39]. In a multivariate analysis, the variables associated with in-hospital
mortality were age, the origin of the bacteremia, and the presence of immunosuppression. Diabetes
was not associated with outcome.
Conclusion:  In this cohort of patients with Enterobacteriaceae  bacteremia, diabetes was not
associated with a poorer prognosis.
Background
Enterobacteriaceae  are the dominant causal agents of
Gram-negative bacteremia and are a major cause of mor-
bidity and mortality [1]. The prevalence of diabetes is
increasing worldwide [2]; considering the predisposition
of diabetes patients to Enterobacteriaceae bacteremia [3],
the number of patients with both diabetes and bacteremia
caused by Enterobacteriaceae is likely to increase as well.
However, information about the effect of diabetes on the
prognosis of patients with infections in general, and with
Enterobacteriaceae bacteremia in particular, is limited. In
addition, some data are contradictory [3-6]. It is signifi-
cant to determine whether diabetes has a negative impact
on the prognosis of Enterobacteriaceae bacteremia so this
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Table 1: Characteristics of diabetic and non-diabetic patients with bacteremia due to Enterobacteriaceae.
Diabetics
n = 181
Non-diabetics
n = 931
p-value RR* (95% CI)
Demographics
Male 88 (48.6) 521 (51.4) 0.07 0.78 (0.59–1.01)
Age, years (mean ± SD) 75.4 ± 11.9 70 ± 16.6 <0.001 -
Nosocomial 24 (13.3) 119 (13) 0.9 1.02 (0.69–1.51)
ICU-acquired 1 (0.6) 10 (1.1) 1 0.55 (0.09–3.6)
Treated in ICU 8 (4.4) 48 (5.2) 0.42 0.87(0.45–1.67)
Postsurgical 4 (2.2) 33 (3.6) 0.5 0.65 (0.26–1.67)
Severe sepsis or shock 32 (17.7) 130 (14) 0.21 1.25 (0.89–1.77)
Adequate empirical antibiotic 150 (84.7) 751 (81.6) 0.39 1.21 (0.83–1.77)
Blood glucose concentration, mg/dL (mean ± SD) 236 ± 103 143 ± 50 <0.001 -
Comorbidities
COPD** 25 (13.8) 89 (9.6) 0.12 1.4 (0.96–2.03)
Ictus 15 (8.3) 48 (5.2) 0.11 1.5 (0.94–2.38)
Cirrhosis 11 (6.1) 50 (5.4) 0.72 1.11 (0.64–1.93)
Chronic renal failure 12 (6.6) 24 (2.6) 0.01 2.11 (1.31–3.43)
Immunosuppression 4 (2.2) 48 (5.2) 0.12 0.46 (0.18–1.19)
Cardiac failure 19 (10.5) 41 (4.4) 0.002 2.05 (1.38–3.05)
Origin of infection
Urinary 100 (55.9) 479 (51.9) 0.37 1.14 (0.87–1.5)
Biliary 34 (19) 166 (18) 0.75 1.06 (0.75–1.49)
Unknown 24(13.4) 138 (15) 0.65 0.9 (0.6–1.34)
Intraabdominal 7 (3.9) 52 (5.6) 0.47 0.72 (0.35–1.46)
Pneumonia 4 (2.2) 26 (2.8) 0.81 0.82 (0.33–2.05)
Microorganism
E. coli 135 (74.6) 726 (78.3) 0.28 0.84 (0.62–1.14)
Klebsiella spp. 19 (10.5) 62 (6.7) 0.09 1.49 (0.98–2.26)
Other 27 (14.9) 139 (15) 1 1 (0.69–1.461BMC Infectious Diseases 2009, 9:94 http://www.biomedcentral.com/1471-2334/9/94
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would support the convenience of a more aggressive
approach for these patients. We performed a retrospective
cohort study to identify possible correlations between dia-
betes and prognosis in patients with Enterobacteriaceae
bacteremia.
Methods
The Sierrallana Hospital is an adult acute-care center in
Torrelavega, a city in the province of Cantabria, Spain that
forms part of a health district of 160,000 inhabitants. It is
a teaching institution with 250 beds that has approxi-
mately 8000 admissions and 65000 assistances at the
emergency service annually. It includes most major
departments and specialties, except transplantation, tho-
racic, cardiovascular surgery and neurosurgery units.
Using the microbiology laboratory database, we identi-
fied patients with Enterobacteriaceae bacteremia who were
treated at Hospital Sierrallana, from January 1997
through June 2007. Only the first episode of bacteremia in
a particular patient, accounted at our hospital during the
period of study, was included. Enterobacteriaceae strains
recovered from blood samples were identified and tested
for antimicrobial susceptibility by the automated testing
systems MicroScan (Dade Behring, Sacramento, CA, USA)
or BD Phoenix (Becton-Dickinson Biosciences, Sparks,
MD, USA).
A standardized data collection form was used to review
the hospital records of the included patients. Diabetes was
considered present if there was a previous diagnosis of
type 1 or type 2 diabetes, or if diabetes was diagnosed dur-
ing the patient's treatment for bacteremia. For the diagno-
sis of diabetes the American Diabetes Association
diagnostic criteria were used [7]. Renal insufficiency was
indicated by a creatinine value ≥ 2.0 mg/dL. Neutropenia
was defined as an absolute neutrophil count of <500 cells/
mm3 at the bacteremia onset. Immunosuppression was
defined as the presence of neutropenia, infection with the
human immunodeficiency virus or current treatment with
immunosuppressive agents. Sepsis, severe sepsis and sep-
tic shock were defined according to the guidelines of Bone
et al [8]. The initial empirical antimicrobial therapy was
considered appropriate if the antibiotics were adminis-
tered within 24 h of acquisition of a blood culture sample
and included at least one antibiotic that was active in vitro
against the causative microorganism(s). Therapy with uri-
nary antiseptics such as norfloxacin, fosfomycin, pipe-
midic acid or nalidixic acid was considered inadequate.
A significance level of 0.05 (2-sided) was used for all tests.
Relative risk (RR) was calculated as the ratio of the inci-
dence rate in patients exposed to a risk factor to the inci-
dence rate in those not exposed. Univariate analyses and
logistic regression were performed to identify factors asso-
ciated with patient death. Factors were added to the model
using variables with a p-value <0.1 in the univariate anal-
ysis. Diabetes was included as a variable in the regression
model independent of the p-value. The statistical analyses
were performed using SPSS software, version 14.0. The
study was approved by the Comité Etico de Investigación
Clínica de Cantabria.
Results
During the study period, 1134 cases of Enterobacteriaceae
bacteremia were identified; of these, full medical records
were available for 1112 (98%). We identified 181
(16.3%) patients with a diagnosis of diabetes, and 90
(8.1%) patients died while undergoing treatment for bac-
teremia. The following Enterobacteriaceae  were isolated
from the blood cultures: Escherichia coli in 862 (77.5%)
patients, Klebsiella spp. in 82 (7.4%) patients, Proteus mira-
bilis in 51 (4.6%) patients, Salmonella spp. in 42 (3.8%)
patients,  Enterobacter  spp. in 36 (3.2%) patients, Mor-
ganella morgagnii in 12 (1.1%) patients, Citrobacter spp. in
11 (1%) patients, Serratia marcescens in 9 (0.8%) patients,
Pantoea agglomerans in 5 (0.4%) patients and Leclercia ade-
carboxylata and Yersinia enterocolitica in one patient each.
Comparing the characteristics of diabetic and non-dia-
betic patients, significant differences in sex, age, comor-
bidities and initial blood glucose concentration were
detected (Table 1). The proportion of patients with bacter-
emia caused by Klebsiella spp. reached borderline statisti-
cal significance. Mortality was 7.2% (13/181) for diabetic
patients and 8.2% (76/927) for non-diabetic patients (p =
0.39).
Variables significantly associated with mortality in the
univariate analysis are shown in Table 2. As nosocomial
and community acquired bacteremia are quite different
entities in terms of risk factors and prognosis a stratified
analysis was performed analyzing variables associated
with prognosis in these subgroups (Table 3 and Table 4).
Polymicrobial 20 (11) 70 (7.6) 0.14 1.41 (0.93–2.12)
Death 13 (7.2) 76 (8.2) 0.77 1.13 (0.67–1.9)
Length of hospital stay, days (mean ± SD) 13.3 ± 12 13.9 ± 15 0.64
Data are n (%) otherwise indicated
*RR: Relative risk
**COPD: chronic obstructive pulmonary disease
Table 1: Characteristics of diabetic and non-diabetic patients with bacteremia due to Enterobacteriaceae. (Continued)BMC Infectious Diseases 2009, 9:94 http://www.biomedcentral.com/1471-2334/9/94
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Table 2: Risk factors for mortality in the entire cohort.
Exitus
n = 90
Surviving
n = 1022
p-value RR* (95% CI)
Demographics
Male 55 (61.1) 558 (54.6) 0.14 1.27 (0.85–1.91)
Age, years (mean ± SD) 76.8 ± 12.47 70.4 ± 16.2 <0.001
Severe sepsis or shock 52 (58.4) 110 (10.8) <0.001 8.21 (5.57–12.1)
Adequate empirical antibiotic 63 (70.8) 838 (83) 0.004 0.53 (0.34–0.81)
Blood glucose concentration, mg/dL (mean ± SD) 164 ± 78 157 ± 70 0.85
Comorbidities
COPD** 10 (11.2) 104 (10.2) 0.44 1.1 (0.59–2.07)
Ictus 8 (9) 55 (5.4) 0.13 1.64 (0.83–3.24)
Cirrhosis 7 (7.9) 54 (5.3) 0.21 1.47 (0.71–3.03)
Chronic renal failure 9 (10) 28 (2.7) 0.006 2.94 (1.54–5.61)
Immunosuppression 10 (11.2) 42 (4.1) 0.006 2.57 (1.42–4.67)
Cardiac failure 11 (12.4) 49 (4.8) 0.006 2.46 (1.39–4.38)
Diabetes 13 (14.6) 168 (16.5) 0.39 0.88 (0.5–1.54)
Origin of infection
Urinary 19 (21.6) 561 (55.1) <0.001 0.25 (0.15–0.41)
Biliary 16 (18.2) 185 (18.2) 0.55 1 (0.6–1.68)
Unknown 22 (25) 140 (13.8) 0.007 1.89 (1.20–2.97)
Intraabdominal 7 (8) 52 (5.1) 0.18 1.89 (0.74–3.17)
Pneumonia 14 (15.9) 16 (1.6) <0.001 6.79 (4.37–10.6)
Microorganism
E. coli 57 (63.3) 805 (78.8) 0.001 0.5 (0.33–0.75)
Klebsiella spp. 9 (10) 73 (7.1) 0.21 1.4 (0.73–2.68)
Proteus spp. 5 (5.6) 47 (4.6) 0.41 1.2 (0.51–2.83)
Citrobacter spp. 2 (2.2) 9 (0.9) 0.22 2.28 (0.64–8.1)
Enterobacter spp. 6 (6.7) 30 (2.9) 0.06 2.14 (1–4.56)
Serratia marcescens 2 (2.2) 7 (0.7) 0.16 2.79 (0.81–9.61)BMC Infectious Diseases 2009, 9:94 http://www.biomedcentral.com/1471-2334/9/94
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Morganella morgagnii 3 (3.3) 9 (0.9) 0.07 3.16 (1.16–8.6)
Salmonella spp. 5 (5.6) 37 (3.6) 0.25 1.5 (0.64–3.5)
Polymicrobial 14 (15.6) 76 (7.4) 0.01 2.09 (1.23–3.54)
Univariate risk estimates are given
Data are n (%) otherwise indicated
*RR: Relative risk.
**COPD: chronic obstructive pulmonary disease
Table 2: Risk factors for mortality in the entire cohort. (Continued)
Table 3: Risk factors for mortality in patients with nosocomial bacteremia
Exitus
n = 19
Surviving
n = 124
p-value RR* (95% CI)
Demographics
Male 15 (78.9) 76 (61.3) 0.03 2.14 (0.75–6.12)
Age, years (mean ± SD) 73 ± 9.27 71.9 ± 13.75 0.01
Severe sepsis or shock 11 (57.9) 19 (15.2) <0.001 5.18 (2.31–11.8)
Adequate empirical antibiotic 16 (80) 93 (78.8) 0.59 1.37 (0.43–4.38)
Blood glucose concentration, mg/dL (mean ± SD) 138.2 ± 58.1 144.8 ± 64.8 0.95
Comorbidities
COPD** 5 (26.3) 17 (13.7) 0.17 1.96 (0.75–4.71)
Ictus 2 (10.5) 6 (4.8) 0.29 1.99 (0.56–7.19)
Cirrhosis 0 8 (6.4) 0.6
Chronic renal failure 5 (26.3) 1 (0.8) <0.001 8.16 (4.42–15.04)
Immunosuppression 2 (10.5) 5 (4) 0.23 2.29 (0.65–8)
Cardiac failure 5 (26.3) 12 (9.7) 0.05 2.65 (1.09–6.43)
Diabetes 3 (15.8) 21 (16.9) 0.6 0.93 (0.29–2.94)
Origin of infection
Urinary 1 (5) 50 (40.3) 0.002 0.1 (0.01–0.72)
Biliary 2 (10.5) 22 (17.9) 0.34 1.07 (0.93–1.23)
Unknown 6 (30) 24 (20) 0.24 1.72 (0.72–4.15)
Intraabdominal 2 (10.5) 18 (14.6) 1 0.72 (0.18–2.87)
Pneumonia 5 (26.3) 3 (2.4) 0.001 5.67 (2.76–11.62)BMC Infectious Diseases 2009, 9:94 http://www.biomedcentral.com/1471-2334/9/94
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Variables that were associated with in-hospital mortality
in the multivariate analysis in the whole cohort, in noso-
comial cases and in community acquired cases are
reflected in Table 5. The severity of sepsis was not
included in the initial models [9]. Diabetes was not asso-
ciated with outcome in these analyses. In a second analy-
sis including the severity of sepsis in the whole cohort, in
the nosocomial cases and in community acquired cases,
diabetes was not associated with outcome.
Discussion
Diabetes has traditionally been associated with a worse
prognosis for patients with infectious diseases such as
Enterobacteriaceae  bacteremia [3], liver abscess [4] and
tuberculosis [6]. However, the prognosis of diabetic
patients has improved in recent years for some proce-
dures, such as coronary bypass grafting [10], and for some
conditions, such as myocardial infarction [11]. This
improvement has been attributed, at least in part, to better
glucose control in diabetics. A similar improvement
would be expected for the prognosis of diabetic patients
with bacterial infections, which is what we found in this
study. Another recent study also found no differences in
the outcomes of diabetic patients with community-
acquired bacteremia [5]. Improvements in glucose control
in diabetic patients may account for the discordance
between our results and those of Thomsen et al [3]; this
group found a slightly higher risk of late death in diabetic
patients in a population study of patients with Enterobac-
teriaceae bacteremia conducted from 1992 through 2001.
Other explanations could be related to differences in the
population analyzed, comorbidities and the adequacy of
antibiotic empirical treatment. We included some varia-
bles that were not analyzed by Thomsen et al, which could
also contribute to the difference in results. In addition, we
only evaluated the effect of diabetes on in-hospital mor-
tality, not on 30- and 90-day mortality [3]. Our study is
the first one which analyzes the mortality of diabetic
patients with bacteremia performed in Mediterranean
country. The protective effect of the Mediterranean diet
over our diabetic patients with bacteremia cannot be dis-
carded.
The mortality in our series is lower that previous similar
studies [3]. Several factors, such as a lower incidence of co-
morbidity, the low proportion of patients with septic
shock and the high proportion of adequate empirical
treatment among our patients with Enterobacteriaceae
bacteraemia may contribute to the low mortality [12]. The
incidence of Enterobacteriaceae bacteremia in our series
in much higher than in others [3,13]; this suggest that the
lower mortality are due to a more vigilant attitude in our
centre that lead to the detection of more mild cases of bac-
teremia.
Our study has several potential limitations. The differ-
ences in mortality could be lower that the sample size
would permit to detect. As the data, including the diagno-
sis of diabetes has been obtained retrospectively, this
could lead to information bias between exposure and out-
Microorganism
E. coli 8 (42.1) 89 (71.2) 0.01 0.34 (0.15–0.8)
Klebsiella spp. 4 (20) 19 (15.2) 0.51 1.39 (0.51–3.82)
Proteus spp. 1 (5.3) 3 (2.4) 0.44 1.93 (0.34–11.12)
Citrobacter spp. 1 (0.8) 0 0.86
Enterobacter spp. 3 (15.8) 9 (7.3) 0.2 2.05 (0.69–6.04)
Serratia marcescens 03  ( 2 . 4 ) 1
Morganella morgagnii 2 (10.5) 1 (0.8) 0.05 5.49 (2.19–13.71)
Salmonella spp. 0 0
Polymicrobial 3 (15) 7 (5.6) 0.13 2.49 (0.87–7.14)
Univariate risk estimates are given
Data are n (%) otherwise indicated
*RR: Relative risk
**COPD: chronic obstructive pulmonary disease
Table 3: Risk factors for mortality in patients with nosocomial bacteremia (Continued)BMC Infectious Diseases 2009, 9:94 http://www.biomedcentral.com/1471-2334/9/94
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Table 4: Risk factors for mortality in patients with community acquired bacteremia.
Exitus
n = 70
Surviving
n = 894
p-value RR (95% CI)
Demographics
Male 39 (55.7) 479 (53.7) 0.8 1.08 (0.69–1.7)
Age, years (mean ± SD) 78.1 ± 12.8 70.1 ± 16.5 <0.001
Severe sepsis or shock 41 (58.6) 91 (10.2) <0.001 8.91 (5.75–13.82)
Adequate empirical antibiotic 47 (68.1) 746 (83.6) 0.002 0.45 (0.28–0.73)
Blood glucose concentration, mg/dL (mean ± SD) 170.9 ± 80.4 158.6 ± 70.2 0.44
Comorbidities
COPD** 5 (7.1) 86 (9.6) 0.67 0.74 (0.31–1.78)
Ictus 6 (8.6) 49 (5.5) 0.28 1.55 (0.7–3.42)
Cirrhosis 7 (10) 46 (5.1) 0.08 1.91 (0.84–1.04)
Chronic renal failure 3 (4.3) 27 (3) 0.47 1.39 (0.47–4.18)
Immunosuppression 8 (11.4) 37 (4.1) 0.01 2.64 (1.35–5.16)
Cardiac failure 6 (8.6) 36 (4) 0.08 2.06 (0.95–4.48)
Diabetes 10 (14.3) 146 (16.3) 0.4 0.86 (0.45–1.65)
Origin of infection
Urinary 18 (26.5) 511 (57.1) <0.001 0.3 (0.18–0.5)
Biliary 13 (19.1) 163 (18.2) 0.87 1.06 (0.59–1.89)
Unknown 16 (23.5) 120 (13.4) 0.03 1.87 (1.1–3.18)
Intraabdominal 5 (7.4) 33 (3.7) 0.18 1.93 (0.83–4.52)
Pneumonia 9 (13.2) 13 (1.5) <0.001 6.53 (3.73–11.42)
Microorganism
E. coli 48 (68.6) 716 (79.8) 0.03 0.58 (0.36–0.94)
Klebsiella spp. 5 (7.1) 54 (6) 0.43 1.18 (0.5–2.83)
Proteus spp. 4 (5.7) 44 (4.9) 0.46 1.16 (0.44–3.05)
Citrobacter spp. 2 (2.9) 8 (0.9) 0.16 2.82 (0.8–9.93)
Enterobacter spp. 3 (4.3) 21 (2.3) 0.25 1.76 (0.6–5.2)
Serratia marcescens 2 (2.9) 4 (0.4) 0.06 4.71 (1.49–14.95)BMC Infectious Diseases 2009, 9:94 http://www.biomedcentral.com/1471-2334/9/94
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come, so the diagnosis of diabetes may actually have been
missed in patients dying precipitously, and conversely
there is a risk that a diagnosis of diabetes has been
wrongly inferred from hyperglycemia in some surviving
patients. We did not routinely collect measures of long-
term glucose control, such as HbA1c, which would have
allowed us to distinguish the effects of long-term poorly-
controlled diabetes on patient prognosis. Finally, our
population was mainly elderly people with type II diabe-
tes, thus, these results may not be applicable to patients
diagnosed with type I diabetes.
Our data suggest that the presence of diabetes is not
related to in-hospital mortality in patients with Enterobac-
teriaceae bacteremia. Improved management of diabetic
patients with acute illnesses in recent years may account
for the absence of an effect of diabetes on outcomes in
these patients.
Conclusion
In conclusion, in our cohort of patients with Enterobacte-
riaceae  bacteremia, diabetes was not associated with a
poorer prognosis. Improved management of diabetic
patients with acute illnesses in recent years may account
for the absence of an effect of diabetes on outcomes in
these patients.
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